Loading…
NRx Pharmaceuticals, Inc. is projected to rise to $5.75 by 2027, a +40% move from its current price of $4.11. NRXP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.95 | $4.11 | $4.28 | +0.10% |
| Jul 13 | $3.89 | $4.12 | $4.36 | +0.20% |
| Jul 14 | $3.85 | $4.12 | $4.42 | +0.31% |
| Jul 15 | $3.81 | $4.13 | $4.47 | +0.41% |
| Jul 16 | $3.78 | $4.13 | $4.52 | +0.51% |
| Jul 17 | $3.75 | $4.14 | $4.56 | +0.61% |
| Jul 18 | $3.72 | $4.14 | $4.60 | +0.72% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.72 | $4.14 | $4.60 | +0.72% |
| Week 2 | $3.59 | $4.17 | $4.84 | +1.44% |
| Week 3 | $3.50 | $4.20 | $5.04 | +2.16% |
| Week 4 | $3.42 | $4.23 | $5.23 | +2.90% |
| Week 5 | $3.36 | $4.26 | $5.40 | +3.63% |
| Week 6 | $3.31 | $4.29 | $5.56 | +4.38% |
| Week 7 | $3.26 | $4.32 | $5.72 | +5.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments and develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.
It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. (NRXP) is a healthcare company focused on central nervous system disorders in the United States. The company is currently trading at $4.00 with a market cap of $171.2M and holds a rank of 3733. The stock sits in a near-term technical setup that shows bullish signals in the broader context of a volatile frontier market.
The current price is $4.00 with a market cap of $171.2M, and it is ranked 3733. The price landscape is supported by a technical backdrop that features bullish sentiment and notable moving averages, with a 30-day trading window that defines the recent price range.
Near-term volatility is indicated by an annualized volatility of 80%, suggesting sizable price swings within the current trading regime. The overall price outlook for the asset combines a bullish multi-year forecast with a stable near-term technical stance as of the data provided.
A major floor 58.6% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 26.1% above — clearing it would confirm fresh momentum.
Key NRXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.07 | Buy | $4.07 | Buy |
| MA 10 | $3.99 | Buy | $4.01 | Buy |
| MA 20 | $3.92 | Buy | $3.94 | Buy |
| MA 50 | $3.68 | Buy | $3.64 | Buy |
| MA 100 | $2.92 | Buy | $3.23 | Buy |
| MA 200 | $2.73 | Buy | $2.92 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.06 | Neutral |
| Stoch RSI (14) | 94.40 | Sell |
| CCI (20) | 139.42 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 11.44 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.30 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 53.94 | Neutral |
| Momentum (10) | 0.63 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.12 | Sell |
| ADX (14) | 14.17 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture shows bullish sentiment with RSI(14) at 60. The stock trades above the 50-day simple moving average ($3.51) and above the 200-day simple moving average ($2.69), with a defined support at $2.97 and a resistance at $4.62. The 30-day range spans from $3.00 to $5.33, illustrating a reasonably wide trading window and ongoing volatility.
Overall, the near-term picture is shaped by bullish indicators embedded in a volatile setup, with a 30-day trading range indicating potential for upside while facing defined resistance near $4.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.68 | $4.11 | $6.23 | 0% | Neutral | |
| $4.38 | $5.75 | $8.09 | +40% | Bullish | |
| $4.75 | $6.51 | $9.64 | +58% | Bullish | |
| $5.36 | $7.62 | $11.74 | +85% | Bullish | |
| $5.55 | $8.15 | $12.97 | +98% | Bullish | |
| $7.05 | $10.66 | $17.45 | +159% | Bullish | |
| $9.34 | $14.52 | $24.39 | +253% | Bullish | |
| $10.09 | $16.12 | $27.69 | +292% | Bullish | |
| $11.08 | $18.17 | $31.87 | +342% | Bullish | |
| $10.44 | $17.54 | $31.36 | +327% | Bullish | |
| $18.98 | $35.79 | $69.31 | +771% | Bullish | |
| $38.30 | $85.11 | $184.65 | +19.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.68 | $4.11 | $5.24 | +0.00% |
| August 2026 | $3.72 | $4.44 | $5.50 | +8.14% |
| September 2026 | $3.73 | $4.51 | $5.67 | +1.48% |
| October 2026 | $3.93 | $4.79 | $6.10 | +6.25% |
| November 2026 | $4.02 | $4.94 | $6.36 | +3.06% |
| December 2026 | $3.87 | $4.79 | $6.23 | -3.00% |
Click any year to see its month-by-month NRXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NRXP to range from $1.68 to $6.23 through 2026. The $4.11 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NRXP price prediction for 2027 points to an average of $5.75 (low $4.38, high $8.09) — a potential gain of +40% on today's $4.11. Momentum favours further upside here.
In 2028, NRXP is projected to trade between $4.75 and $9.64, averaging $6.51 — a potential gain of +58% from today's $4.11. That is up +13% on the projected 2027 average. Buyers look set to stay in control over this stretch.
NRx Pharmaceuticals, Inc.'s 2029 outlook centres on $7.62, within a $5.36 to $11.74 range. That is up +17% on the projected 2028 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2030, NRXP could reach as high as $12.97, with a base case around $8.15 and support toward $5.55 — roughly +98% from $4.11. Buyers look set to stay in control over this stretch.
Expect NRXP to range from $7.05 to $17.45 through 2031. The $10.66 average target implies a +159% move from current prices. That is up +31% on the projected 2030 average. Momentum favours further upside here.
The NRXP price prediction for 2032 points to an average of $14.52 (low $9.34, high $24.39) — a potential gain of +253% on today's $4.11. Buyers look set to stay in control over this stretch.
In 2033, NRXP is projected to trade between $10.09 and $27.69, averaging $16.12 — a potential gain of +292% from today's $4.11. That is up +11% on the projected 2032 average. Momentum favours further upside here.
NRx Pharmaceuticals, Inc.'s 2034 outlook centres on $18.17, within a $11.08 to $31.87 range. That is up +13% on the projected 2033 average. That marks a +342% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NRXP could reach as high as $31.36, with a base case around $17.54 and support toward $10.44 — roughly +327% from $4.11. Momentum favours further upside here.
Expect NRXP to range from $18.98 to $69.31 through 2040. The $35.79 average target implies a +771% move from current prices. That is up +104% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NRXP price prediction for 2050 points to an average of $85.11 (low $38.30, high $184.65) — a potential gain of +19.7x on today's $4.11. Momentum favours further upside here.
Investing $1,000 in NRXP today (≈ 243.309002 NRXP) could be worth
$20,707.25
+$19,707.25 (+1971%) by 2050 · US Dollar
Based on the average projected NRXP price of $85.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRXPwould be worth at today's price.
$1,000 invested in NRXP on Jul 10, 2025 (≈ 305.810399 NRXP) would be worth
$1,256.88
+$256.88 (+25.7%) today · 1.26× · US Dollar
Based on a NRXP entry price of $3.27 vs. today's $4.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.87 | $1,062.02 | +6.2% |
| 1 month ago | $3.76 | $1,093.09 | +9.3% |
| 3 months ago | $2.22 | $1,851.35 | +85.1% |
| 6 months ago | $2.22 | $1,851.35 | +85.1% |
| 1 year ago | $3.27 | $1,256.88 | +25.7% |
| All time (5.0y) ago | $96.5 | $42.59 | -95.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRXP forecast.
Our base-case forecast reaches $8.20 around 2031.
Implied market cap at $8.20: $350.96M
The multi-year forecast shows a structured path of upside with the average price rising from $4.00 in 2026 to $83.42 by 2050, accompanied by substantial ROI expansion. In 2026 the average is $4.00 with a min of $1.68 and a max of $6.14 and an ROI of 0, signaling a neutral outlook for that year. From 2027 onward, annual averages expand to $5.80 (ROI 45), $6.39 (ROI 59.7), $7.41 (ROI 85.3), and $8.06 (ROI 101.5) in 2030, all with bullish sentiment.
The forecast continues to accelerate: 2031 average $10.24 (ROI 156.1), 2032 $14.40 (ROI 260), 2033 $16.32 (ROI 307.9), 2034 $17.67 (ROI 341.7), and 2035 $17.02 (ROI 325.5), all bullish. By 2040, the average reaches $35.38 (ROI 784.4), and by 2050 the average is $83.42 (ROI 1985.5), maintaining a bullish stance throughout the horizon. These figures reflect sizable upside potential but are not guarantees, and outcomes will depend on market dynamics and execution.
The forecasted path underscores meaningful upside for longer horizons while acknowledging inherent investment risk.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $8.06, with a min of $5.35 and max of $13.15; ROI 101.5; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROI: 2027 avg $5.80, ROI 45; 2028 avg $6.39, ROI 59.7; 2029 avg $7.41, ROI 85.3, and beyond, indicating upside potential under the given assumptions.
Yes. The 2040 forecast shows a max of $70.93, indicating a potential to reach around $70 within the horizon; the later years also show higher possible maxima, such as $188.38 in 2050.
The 2026 forecast shows an average price of $4.00, with a min of $1.68 and a max of $6.14; the implied ROI for that year is 0 and sentiment is NEUTRAL.
Beyond 2030, the forecast envisions continued upside, with 2040 average $35.38 and 2050 average $83.42; ROIs are 784.4 and 1985.5 respectively, with sentiment staying BULLISH across these horizons.
NRx Pharmaceuticals, Inc. Community Discussion
0Share your NRx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.